Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 76, Issue 1, 2016, Pages 33-39

  Wei, Qiu Shi ^a,b   Huang, Li ^a   Tan, Xin ^a   Chen, Zhen Qiu ^b   Chen, Si Min ^a   Deng, Wei Min ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

bone mineral density; Osteopontin; osteoporosis; postmenopausal women

Indexed keywords

25 HYDROXYVITAMIN D; CARBOXY TERMINAL CROSS LINKING TELOPEPTIDE OF TYPE I COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE; PROCOLLAGEN; PROCOLLAGEN TYPE I AMINOPROPEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; TNFSF11 PROTEIN, HUMAN;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CHINA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SPINE FRACTURE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHEMISTRY; FEMUR; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; REGRESSION ANALYSIS;

ABSORPTIOMETRY, PHOTON; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; BONE DENSITY; CHINA; FEMALE; FEMUR; HUMANS; MIDDLE AGED; OSTEOPONTIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; POSTMENOPAUSE; RANK LIGAND; REGRESSION ANALYSIS;

EID: 84947864857     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2015.1087045     Document Type: Article

References (26)

1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.
2. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87.
3. Walker CG, Dangaria S, Ito Y, Luan X, Diekwisch TG. Osteopontin is required for unloading-induced osteoclast recruitment and modulation of RANKL expression during tooth drift-associated bone remodeling, but not for super-eruption. Bone 2010;47:1020-9.
4. Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi DT, Miller TA. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 2004;34:799-808.
5. Franzén A, Hultenby K, Reinholt FP, Onnerfjord P, Heinegard D. Altered osteoclast development and function in osteopontin deficient mice. J Orthop Res 2008;26:721-8.
6. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomyinduced bone resorption. Proc Natl Acad Sci USA 1999;96:8156-60.
7. Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001;193:399-404.
8. Ishijima M, Ezura Y, Tsuji K, Rittling SR, Kurosawa H, Denhardt DT, Emi M, Nifuji A, Noda M. Osteopontin is associated with nuclear factor kappaB gene expression during tail-suspension-induced bone loss. Exp Cell Res 2006;312:3075-83.
9. Cho EH, Cho KH, Lee HA, Kim SW. High serum osteopontin levels are associated with low bone mineral density in postmenopausalwomen. J Korean Med Sci 2013;28:1496-9.
10. Fodor D, Bondor C, Albu A, Simon SP, Craciun A, Muntean L. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. J Investig Med 2013;61:15-21.
11. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 2010;21:1401-9.
12. Méndez JP, Rojano-Meja D, Pedraza J, Coral-Vázquez RM, Soriano R, Garca-Garca E, Aguirre-Garca Mdel C, Coronel A, Canto P. Bone mineral density in postmenopausal Mexican-Mestizo women with normal body mass index, overweight, or obesity. Menopause 2013;20:568-72.
13. Gómez-Ambrosi J, Catalán V, Ramrez B, Rodrguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA, Salvador J, Frühbeck G. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007;92:3719-27.
14. Lu HK, Zhang Z, Ke YH, He JW, Fu WZ, Zhang CQ, Zhang ZL. High prevalence of vitamin D insufficiency in China: relationship with the levels of parathyroid hormone and markers of bone turnover. PLoS One 2012;7:e47264.
15. Garnero P, Munoz F, Sornay-Rendu E. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007;40:716-22.
16. El Maghraoui A, Ouzzif Z, Mounach A, Rezqi A, Achemlal L, Bezza A, Tellal S, Dehhaoui M, Ghozlani I. Hypovitaminosis D and prevalent asymptomatic vertebral fractures in Moroccan postmenopausal women. BMC Womens Health 2012;12:11.
17. Mehrotra RN, Ranjan A, Lath R. Postmenopausal osteoporosis: our experience. Indian J Endocrinol Metab 2012;16:S421-2.
18. von Mühlen DG, Greendale GA, Garland CF, Wan L, Barrett-Connor E. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: The Rancho Bernardo Study. Osteoporos Int 2005;16:1721-6.
19. van der Meijden K, Lips P, van Driel M, Heijboer AC, Schulten EA, den Heijer M, Bravenboer N. Primary human osteoblasts in response to 25-hydroxyvitamin D3, 1, 25-dihydroxyvitamin D3 and 24R, 25-dihydroxyvitamin D3. PLoS One 2014;9:e110283.
20. Suda T, Masuyama R, Bouillon R, Carmeliet G. Physiological functions of vitamin D: what we have learned from global and conditional VDR knockout mouse studies. Curr Opin Pharmacol 2015;22:87-99.
21. Chiang TI, Chang IC, Lee HS, Lee H, Huang CH, Cheng YW. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormonetreatment. Osteoporos Int 2011;22:577-85.
22. Albadah MS, Dekhil H, Shaik SA, Alsaif MA, Shogair M, Nawaz S, Alfadda AA. Effect of weight loss on serum osteocalcin and its association with serum adipokines. Int J Endocrinol 2015;2015:508532.
23. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-64.
24. Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, Miki T, Kim M, Nishizawa Y. Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother 2003;57: 98-104.
25. Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKLmediated NF-kB and MAPK signaling pathways. J Bone Miner Res 2011;26:644-56.
26. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-30.